Pemigatinib is an oral, potent, selective FGFR1-3 inhibitor for treatment of adults with previously treated, unresectable, locally advanced or metastatic CCA with FGFR2 fusions or other rearrangements.28 Here, FGFR2 is linked to cholangiocarcinoma.